Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on October 10, 2008. The report details corporate governance changes effective immediately on the date of the report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Election of Director: Robert J. Alpern, M.D., Dean of the Yale School of Medicine, was named to the Abbott Board of Directors.
- By-Law Amendment: The Board amended Article III, Section 2 of the By-Laws to increase the number of directors from thirteen to fourteen persons.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the effective date of Robert J. Alpern's appointment to the Board.
- Confirm the updated total number of directors is fourteen as per the amended By-Laws.
- Review the attached Exhibit 3.1 for the full text of the amended and restated By-Laws.